Form 4: Cidara Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Carin Canale-Theakston acquired stock options in Cidara Therapeutics, Inc. on July 18, 2024.
Summary
- Carin Canale-Theakston, a director of Cidara Therapeutics, Inc., filed a Form 4 on July 19, 2024.
- The filing reports a transaction that occurred on July 18, 2024, where Canale-Theakston acquired 2,125 stock options with an exercise price of $12.64.
- These options vest on the earlier of the first anniversary of the grant date or the day before the Issuer's 2025 annual meeting of stockholders.
- Following the reported transaction, Canale-Theakston directly owns 2,125 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/18/2024 | Date of transaction: Carin Canale-Theakston acquired stock options. |
| 07/19/2024 | Date of Form 4 filing. |
| 07/17/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.